Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fosaprepitant
Drug ID BADD_D00962
Description Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Indications and Usage For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Marketing Status Prescription; Discontinued
ATC Code A04AD12
DrugBank ID DB06717
KEGG ID D10895
MeSH ID C579707
PubChem ID 135413538
TTD Drug ID Not Available
NDC Product Code 71288-418; 67457-888; 71839-104; 16714-120; 43598-948; 70625-311; 68180-690; 72205-083; 69539-181; 63323-972; 72205-026; 60505-6105; 16714-929; 43598-859; 69097-830; 67457-889; 72603-106; 70710-1615; 68001-421; 16729-240; 72205-054; 68001-517; 0591-4385; 0781-3497; 69539-034
Synonyms fosaprepitant | Emend for injection | fosaprepitant dimeglumine | L 785,298 | L785,298 | L-785,298
Chemical Information
Molecular Formula C23H22F7N4O6P
CAS Registry Number 172673-20-0
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C( C=C4)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin lesion23.03.03.010--Not Available
Sneezing22.02.05.011--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Tachycardia02.03.02.0070.000374%Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000374%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Type I hypersensitivity10.01.03.006--Not Available
Unresponsive to stimuli17.02.05.0310.000561%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Visual acuity reduced17.17.01.011; 06.02.03.001--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Subileus07.13.01.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Infusion site induration12.07.05.010; 08.02.05.009--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site pruritus23.03.12.006; 12.07.05.005; 08.02.05.004--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Staphylococcal infection11.02.05.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages